68557-26-6 Usage
Chemical Class
Aminotriazoles
Explanation
Aminotriazoles are a class of organic compounds that contain a triazole ring with an attached amino group. This compound is a derivative of triazole and belongs to this class.
Explanation
The structure of the compound is characterized by a 1,2,4-triazole ring with an amino group at the 5-position, a methyl group at the 3-position, and a phenyl group attached to the 1-position.
Explanation
This compound is commonly used as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds due to its versatile reactivity.
Explanation
Studies have shown that 1H-1,2,4-Triazol-5-amine, 3-methyl-1-phenylexhibits potential biological activities, such as antifungal and antitumor properties, which could be useful in the development of new drugs.
Explanation
Due to its unique structural features and versatile reactivity, this compound has been employed in various chemical reactions and research applications to study its properties and potential uses.
Explanation
The solubility of the compound in different solvents is not mentioned in the provided material. Solubility is an important property for determining the compound's reactivity and potential applications.
Explanation
The stability of the compound under various conditions, such as temperature, pressure, or in the presence of other chemicals, is not mentioned in the provided material. Stability is a crucial factor in determining the compound's suitability for specific applications.
Explanation
The compound is described as having versatile reactivity, which means it can participate in a wide range of chemical reactions, making it a valuable intermediate in the synthesis of various compounds.
Structure
1H-1,2,4-Triazol-5-amine, 3-methyl-1-phenyl-
Applications
Pharmaceutical and agrochemical synthesis
Biological Activities
Antifungal and antitumor properties
Research Applications
Chemical reactions and structural studies
Solubility
Not specified in the material provided
Stability
Not specified in the material provided
Reactivity
Versatile
Check Digit Verification of cas no
The CAS Registry Mumber 68557-26-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,8,5,5 and 7 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 68557-26:
(7*6)+(6*8)+(5*5)+(4*5)+(3*7)+(2*2)+(1*6)=166
166 % 10 = 6
So 68557-26-6 is a valid CAS Registry Number.
68557-26-6Relevant articles and documents
Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators
Sharma, Swagat,Kozek, Krystian A.,Abney, Kristopher K.,Kumar, Sushil,Gautam, Nagsen,Alnouti, Yazen,David Weaver,Hopkins, Corey R.
supporting information, p. 791 - 796 (2019/02/06)
The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.
PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
-
Paragraph 00662, (2014/06/11)
Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
